Intravesical BCG instillations for superficial bladder tumors: A summary for the general practioner;Intravesicale BCG-instillaties voor oppervlakkige blaastumoren: Een samenvatting voor de huisarts

Tijdschrift voor Geneeskunde

Volumn 59, Issue 14-15, 2003, Pages 915-919

  Kerckhaert, W ^a   Oosterlinck, W ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AZITHROMYCIN; BCG VACCINE; BETA LACTAM ANTIBIOTIC; CEPHALOSPORIN; CIPROFLOXACIN; CLARITHROMYCIN; COTRIMOXAZOLE; ERYTHROMYCIN; GENTAMICIN; NITROFURANTOIN; NONSTEROID ANTIINFLAMMATORY AGENT; OFLOXACIN; PARACETAMOL; TOBRAMYCIN; TUBERCULOSTATIC AGENT;

BLADDER CARCINOMA; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PREVENTION; CANCER RECURRENCE; CARCINOMA IN SITU; CHEMOPROPHYLAXIS; DRUG MECHANISM; EPIDIDYMITIS; GENERAL PRACTITIONER; HUMAN; MEDICAL INFORMATION; PROSTATITIS; REVIEW; SIDE EFFECT; STANDARD; SUPERFICIAL CANCER; TRANSITIONAL CELL CARCINOMA; TREATMENT INDICATION; TREATMENT PLANNING; URETER OBSTRUCTION; URETHRITIS;

EID: 0042324905     PISSN: 0371683X     EISSN: None     Source Type: Journal    
DOI: 10.2143/tvg.59.14.5001651     Document Type: Review

References (16)

1. MORALES A, EIDINGER D, BRUCE AW. Intracavitary Bacillus Calmette-Guérin in the treatment of superficial bladder tumors. J Urol 1976; 116: 180-183.
2. OOSTERLINCK, W, LOBEL B, JAKSE J, MALMSTROM PU, STOCKE M, STERNBERG C. Guidelines on bladder cancer. Eur Urol 2002; 41: 105-112.
3. OOSTERLINCK W, KURTH KH, SCHRODER F, BULTINCK J, HAMMOND B, SYLVESTER R. A prospective European Organization for Research and Treatment of Genitourinary Cancer Group comparing transurethral resection followed by a single intravesical instillation of epirubicin or water in single stage Ta, T1 papillary carcinoma of the bladder. J Urol 1993; 149: 749-752.
4. KURTH KH, BOUFFIOUX C, SYLVESTER R, VAN DER MEIJDEN AP, OOSTERLINCK W, BRAUSI M. Treatment of superficial bladder tumors: achievements and needs. Eur Urol 2000; 37 Suppl 3: 1-9.
5. SCHWAIBOLD H, PICHLMEIER U, KLINGENBERGER HJ, HULAND H. Longterm follow-up of cytostatic intravesical instillation in patients with superficial bladder carcinoma. Is short-term intensive instillation better than maintenance therapy? Eur Urol 1997; 31: 153-159.
6. MARTINEZ-PINEIRO JA, MARTINEZ-PINEIRO L. BCG update: intravesical therapy. Eur Urol 1997; 31 Suppl 1: 31-41.
7. KURTH KH, SCHELLHAMMER PF, OKAJIMA E, et al. Current methods of assessing and treating carcinoma in situ of the bladder with or without involvement of the prostatic urethra. Int J Urol 1995; 2 Suppl 2: 8-22.
8. BOHLE A. BCG's Mechanism of action - increasing our understanding. Eur Urol 2000; 37 Suppl 1: 1-8.
9. KOLODZIEJ A, DEMBOWSKI J, ZDROJOWY R, WOZNIAK P, LORENZ J. Treatment of high-risk superficial bladder cancer with maintenance bacille Calmette-Guérin therapy: preliminary results. BJU Int 2002; 89: 620-622.
10. DE REIJKE TM, DE BOER EC, KURTH KH, SCHAMHART DH. Urinary interleukin-2 monitoring during prolonged bacillus Calmette-Guérin treatment: can it predict the optimal number of instillations? J Urol 1999; 161: 67-71.
11. ZLOTTA AR, VAN VOOREN JP, HUYGEN K, et al. What is the optimal regimen for BCG intravesical therapy? Are six weekly instillations necessary? Eur Urol 2000; 37: 367-508.
12. MARTINEZ-PINEIRO JA, FLORES N, ISORNA S, et al. Long-term follow-up of a randomized prospective trial comparing a standard 81 mg dose of intravesical bacille Calmette-Guérin with a reduced dose of 27 mg in superficial bladder cancer. BJU Int 2002; 89: 671-680.
13. RISCHMANN P, DESGRANDSCHAMPS F, MALAVAUD B, CHOPIN DK. BCG intravesical instillations: recommandations for side-effects management. Eur Urol 2000; 37 Suppl 1: 33-36.
14. VAN DER MEIJDEN AP. Practical approaches to the prevention and treatment of adverse reactions to BCG. Eur Urol 1995; 27 Suppl 1: 23-28.
15. LAMM DL. Complications of bacillus Calmette-Guérin immunotherapy. Urol Clin North Am 1992; 19: 565-572.
16. DUREK C, RUSCH-GERDES S, JOCHAM D, BOHLE A. Sensitivity of BCG to modern antibiotics. Eur Urol 2000; 37 Suppl 1: 21-25.